연구성과로 돌아가기
2020 연구자 정보 (115 / 997)
※ 컨트롤 + 클릭으로 열별 다중 정렬 가능합니다.
Excel 다운로드
| Author Name | 제1저자 여부 | 교신저자 여부 | Address | ResearcherID | ORCID | Paper Title | WoS Edition | 최상위 JCR(%) | WoS Category | Related Email |
|---|---|---|---|---|---|---|---|---|---|---|
|
Enkhmandal, Orsoo (Enkhmandal, O) |
Natl Univ Mongolia, Ecol Grp, Dept Biol, Sch Arts & Sci, Ulaanbaatar 14201, Mongolia |
|
|
[JCR상위 6.8] Metal-Tolerant Fungal Communities Are Delineated by High Zinc, Lead, and Copper Concentrations in Metalliferous Gobi Desert Soils | SCIE | 6.8 | ECOLOGY;MARINE & FRESHWATER BIOLOGY;MICROBIOLOGY | boldgiv@num.edu.mn;foundinkualalumpur@yahoo.com; | ||
|
Feng, Yin-Hsun (Feng, YH) |
Chi Mei Med Ctr, Tainan, Taiwan |
|
|
[JCR상위 6.8] CONTESSA 2: A multinational, multicenter, phase 2 study of tesetaxel plus a reduced dose of capecitabine in patients with HER2-, HR+ metastatic breast cancer (MBC) who have not previously received a taxane | SCIE | 6.8 | ONCOLOGY | |||
|
Han, Jinil (Han, J) |
Gencurix Inc, Seoul, South Korea |
|
|
[JCR상위 6.8] A novel immune prognostic index for the stratification of high-risk patients with early breast cancer | SCIE | 6.8 | ONCOLOGY | |||
|
Izarzugaza, Yann (Izarzugaza, Y) |
Hosp Univ Fdn Jimenez Diaz, Madrid, Spain |
|
|
[JCR상위 6.8] CONTESSA 2: A multinational, multicenter, phase 2 study of tesetaxel plus a reduced dose of capecitabine in patients with HER2-, HR+ metastatic breast cancer (MBC) who have not previously received a taxane | SCIE | 6.8 | ONCOLOGY | |||
|
Kim, Soujung (Kim, S) |
제1저자 |
Yonsei Univ, Dept Earth Syst Sci, Seoul 03722, South Korea McMaster Univ, Sch Geog & Earth Sci, Hamilton, ON L8S 4K1, Canada |
|
|
[JCR상위 6.8] Petro-tectonic evolution of metamorphic sole of the Semail ophiolite, UAE | SCIE | 6.8 | GEOSCIENCES, MULTIDISCIPLINARY | yirang@kigam.re.kr; | |
|
Kim, Sung-Bae (Kim, SB) |
Univ Ulsan, Coll Med, Asan Med Ctr, Seoul, South Korea |
JXL-8219-2024 Kim, Sung-Bae |
|
[JCR상위 6.8] CONTESSA 2: A multinational, multicenter, phase 2 study of tesetaxel plus a reduced dose of capecitabine in patients with HER2-, HR+ metastatic breast cancer (MBC) who have not previously received a taxane | SCIE | 6.8 | ONCOLOGY | |||
|
Kokkalas, Sotirios (Kokkalas, S) |
Univ Patras, Dept Geol, Patras 26500, Greece |
J-2407-2019 Kokkalas, Sotirios |
0000-0002-5604-0445 Kokkalas, Sotirios |
[JCR상위 6.8] Petro-tectonic evolution of metamorphic sole of the Semail ophiolite, UAE | SCIE | 6.8 | GEOSCIENCES, MULTIDISCIPLINARY | yirang@kigam.re.kr; | ||
|
Koo, Beom-Mo (Koo, BM) |
Seoul Natl Univ, Seoul, South Korea |
|
|
[JCR상위 6.8] A novel immune prognostic index for the stratification of high-risk patients with early breast cancer | SCIE | 6.8 | ONCOLOGY | |||
|
Kwon, Mi Jeong (Kwon, MJ) |
Kyungpook Natl Univ, Daegu, South Korea |
|
|
[JCR상위 6.8] A novel immune prognostic index for the stratification of high-risk patients with early breast cancer | SCIE | 6.8 | ONCOLOGY | |||
|
Lee, Hannah (Lee, H) |
제1저자 | Seoul Natl Univ, Seoul, South Korea |
|
|
[JCR상위 6.8] A novel immune prognostic index for the stratification of high-risk patients with early breast cancer | SCIE | 6.8 | ONCOLOGY | ||
|
Lemieux, Julie (Lemieux, J) |
Univ Laval, CHU Quebec, Ctr Rech, Quebec City, PQ, Canada |
|
|
[JCR상위 6.8] CONTESSA 2: A multinational, multicenter, phase 2 study of tesetaxel plus a reduced dose of capecitabine in patients with HER2-, HR+ metastatic breast cancer (MBC) who have not previously received a taxane | SCIE | 6.8 | ONCOLOGY | |||
|
Liu, Mei-Ching (Liu, MC) |
Koo Fdn, Sun Yat Sen Canc Ctr, Taipei, Taiwan |
|
|
[JCR상위 6.8] CONTESSA 2: A multinational, multicenter, phase 2 study of tesetaxel plus a reduced dose of capecitabine in patients with HER2-, HR+ metastatic breast cancer (MBC) who have not previously received a taxane | SCIE | 6.8 | ONCOLOGY | |||
|
Marx, Gavin (Marx, G) |
Univ Sydney, Sydney Adventist Hosp, Syndney, NSW, Australia |
|
|
[JCR상위 6.8] CONTESSA 2: A multinational, multicenter, phase 2 study of tesetaxel plus a reduced dose of capecitabine in patients with HER2-, HR+ metastatic breast cancer (MBC) who have not previously received a taxane | SCIE | 6.8 | ONCOLOGY | |||
|
O'Connell, Joseph (O'Connell, J) |
Odonate Therapeut Inc, San Diego, CA USA |
|
|
[JCR상위 6.8] CONTESSA 2: A multinational, multicenter, phase 2 study of tesetaxel plus a reduced dose of capecitabine in patients with HER2-, HR+ metastatic breast cancer (MBC) who have not previously received a taxane | SCIE | 6.8 | ONCOLOGY | |||
|
O'Shaughnessy, Joyce (O'Shaughnessy, J) |
Baylor Univ, Med Ctr, Texas Oncol, US Oncol, Dallas, TX USA |
|
|
[JCR상위 6.8] CONTESSA 2: A multinational, multicenter, phase 2 study of tesetaxel plus a reduced dose of capecitabine in patients with HER2-, HR+ metastatic breast cancer (MBC) who have not previously received a taxane | SCIE | 6.8 | ONCOLOGY |
페이지 이동: